A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies (NCT07572006)
A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
🩺 Plain-English Summary (8th-Grade Level)
The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \[RP2D\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone and/or when administered in addition to standard of care (SoC) therapy at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system). For US sites: The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \[RP2D\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system).
Who can join: Review the eligibility criteria below.
Location: Indiana Blood & Marrow Transplantation — Indianapolis, Indiana
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Indiana Blood & Marrow Transplantation — Indianapolis, Indiana
- Start Midwest — Grand Rapids, Michigan
- Rutgers Cancer Institute of New Jersey — Piscataway, New Jersey
- NYU Langone Health — New York, New York
- Sarah Cannon Cancer Institute — Nashville, Tennessee
- MD Anderson Cancer Center - University of Texas — Houston, Texas
- Peter MacCallum Cancer Centre — Melbourne,
- UZ Antwerpen — Edegem,
- Aarhus University Hospital — Aarhus N,
- Institut Paoli Calmettes — Marseille,
- CHU Lyon Sud — Pierre-Bénite,
- Institut Claudius Regaud — Toulouse,
- Hosp Univ Fund Jimenez Diaz — Madrid,
- Clinica Univ. de Navarra — Pamplona,
- The Christie Nhs Foundation Trust — Manchester,
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematologic Neoplasms
- Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion — Durham, North Carolina
- Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil — Los Angeles, California
- A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms — Greenville, South Carolina
- Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial) — Calgary, Alberta
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies — Bethesda, Maryland
Explore by condition: All Hematologic Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.